Page 2 - Revised Upper Limb Module News Today

- Tertiary endpoint data show trends of continuous improvement in activities of daily living, fatigue, and endurance over 24 months - These data indic

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), said that two-year data from the JEWELFISH study, which evaluated Evrysdi (risdiplam) ...

Investegate announcements from F. Hoffmann-La Roche Ltd, Positive new data for Roche’s Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA)

- Positive 24-month data from ongoing Phase 2 TOPAZ trial extension supports potential benefit of apitegromab for patients with Types 2 and 3 Spinal Muscular Atrophy (SMA)- Actively enrolling in pivotal Phase 3 SAPPHIRE clinical trial for apitegromab- Discovery pipeline advancements made for LTBP-TGFβ1 target to tre...

Cognitive function was associated with disease severity and motor impairment in patients with type 3 SMA, suggesting the presence of intrinsic brain pathology.

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it

Long-term efficacy data from the pivotal SUNFISH study confirm increases in motor function are sustained at three years while adverse events decreased over the same periodPart 2 of SUNFISH... | March 16, 2022

New data demonstrates the long-term safety and efficacy of Evrysdi® (risdiplam) in a broad population of people with spinal muscular atrophy.

Investegate announcements from F. Hoffmann-La Roche Ltd, New data for Roche’s Evrysdi (risdiplam) demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophy (SMA)

Long-term efficacy data from the pivotal SUNFISH study confirm increases in motor function are sustained at three years while adverse events decreased over the same periodPart 2 of SUNFISH showed Evrysdi